euro adhoc: curasan AG / other / curasan AG: New Products for Oral Surgery

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

New Products

12.03.2008

curasan AG (ISIN DE 000 549 453 8) listed in the Prime Standard
signed a distributorship agreement with Osteogenics Biomedical Inc.,
Lubbock, Texas, USA.

Thereby, curasan is granted the distribution rights for a powerful
product package expected to be marketed throughout Europe under
curasan´s own brand name as of summer of 2008. The package contains,
among others, five membrane lines with different features, available
in various sizes and shapes, suitable for specific indications.

With this considerable product line extension in the field of dental
surgery and implantology curasan provides known products of optimized
quality as well as new solutions which ideally supplement the
existing range.

These products, the license for which was obtained without
significant advance costs, will contribute substantially to the
planned overproportional growth in sales.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an
exchange-listed company, is a leading innovator within the growth
market of bone and tissue regeneration. The company has developed a
comprehensive product range centred around its synthetic bone
regeneration material Cerasorb®, for use in soft and hard tissue.
With the REVOIS® implant system, the company's sales is focusing more
prominently on the growth market of dental surgery/implantology. The
majority of new products emerging from the substantial development
pipeline are to be offered under licence within other medical fields.
Please visit curasan's corporate website at www.curasan.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Curasan AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Erwin Amashaufer, curasan AG, phone +49 6027 4686-465, email:

ir@curasan.de

Andrea Weidner, curasan AG, phone +49 6027 4686-467, email: pr@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade